{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:23:48Z","timestamp":1770333828007,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.semarthrit.2020.09.014","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T17:18:41Z","timestamp":1607707121000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Drug retention rates of biological agents in adult onset Still's disease"],"prefix":"10.1016","volume":"51","author":[{"given":"Corrado","family":"Campochiaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Farina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Tomelleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Baldissera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Cavalli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.semarthrit.2020.09.014_bib0001","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/1744666X.2017.1332994","article-title":"Treatment of adult-onset still's disease: up to date","volume":"13","author":"Yoo","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.014_bib0002","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3109\/03009742.2014.992949","article-title":"Efficacy and safety of biological agents in adult-onset Still's disease","volume":"44","author":"Cavalli","year":"2015","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.014_bib0003","unstructured":"Giacomelli R., Sota J., Ruscitti P., Campochiaro C., Colafrancesco S., Dagna L., et\u00a0al. The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. Clin Exp Rheumatol (Online ahead of print)."},{"issue":"11","key":"10.1016\/j.semarthrit.2020.09.014_bib0004","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/1744666X.2017.1375853","article-title":"Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies","volume":"13","author":"Ruscitti","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.09.014_bib0005","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1002\/art.27532","article-title":"Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease","volume":"62","author":"Franchini","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.014_bib0006","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fphar.2019.00296","article-title":"Long-term retention rate of anakinra in adult onset Still's disease and predictive factors for treatment response","volume":"10","author":"Vitale","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semarthrit.2020.09.014_bib0007","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3389\/fphar.2019.00918","article-title":"Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease","volume":"10","author":"Sota","year":"2019","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.014_bib0008","first-page":"424","article-title":"Preliminary criteria for classification of adult Still's disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.014_bib0009","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult still's disease: manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine (Baltimore)"},{"issue":"39","key":"10.1016\/j.semarthrit.2020.09.014_bib0010","doi-asserted-by":"crossref","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","article-title":"Efficacy of anakinra in refractory adult-onset still's disease multicenter study of 41 patients and literature review","volume":"94","author":"Ortiz-Sanju\u00e1n","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.014_bib0011","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12016-019-08747-8","article-title":"Autoinflammatory pathogenesis and targeted therapy for adult-onset Still's disease","volume":"58","author":"Li","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.014_bib0012","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerr\u00e9","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.014_bib0013","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3899\/jrheum.111549","article-title":"Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study","volume":"39","author":"Nordstr\u00f6m","year":"2012","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.09.014_bib0014","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.21901","article-title":"Anakinra in adult-onset still's disease: long-term treatment in patients resistant to conventional therapy","volume":"65","author":"Giampietro","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.09.014_bib0015","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fphar.2017.00369","article-title":"Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still's disease: a multicentre retrospective observational study","volume":"8","author":"Colafrancesco","year":"2017","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.014_bib0016","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13075-019-1843-9","article-title":"Efficacy of canakinumab as first-line biologic agent in adult-onset Still's disease","volume":"21","author":"Cavalli","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.09.014_bib0017","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/art.38398","article-title":"Efficacy of tocilizumab in conventional treatment-refractory adult-onset still's disease: multicenter retrospective open-label study of thirty-four patients","volume":"66","author":"Ortiz-Sanju\u00e1n","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.09.014_bib0018","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1080\/14397595.2017.1416924","article-title":"Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: a meta-analysis","volume":"28","author":"Ma","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.014_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","article-title":"Tocilizumab for the treatment of adult-onset Still's disease: results from a case series","volume":"33","author":"Cipriani","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.09.014_bib0020","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset still's disease","volume":"31","author":"Chen","year":"2004","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.014_bib0021","first-page":"396","article-title":"Elevated serum interleukin 6, interferon-y, and tumor necrosis factor-a levels in patients with adult still's disease","volume":"25","author":"Hoshino","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.014_bib0022","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/TCRM.S155488","article-title":"Biological therapy of traditional therapy-resistant adult-onset still's disease: an evidence-based review","volume":"14","author":"Zhou","year":"2018","journal-title":"Ther Clin Risk Manag"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:02:58Z","timestamp":1758733378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0049017220302845"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.014","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug retention rates of biological agents in adult onset Still's disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}